Redeye maintains its estimates with minor changes following Nanologica’s Q2 2023 report, on which we...
Redeye is pleased to see the new framework agreement with the French Ministry of Defense recently an...
Taaleri announced first closing of new flagship fund SolarWind III at EUR 286m.
Idogen's efforts of a reverse merger have been unsuccesful and the company has now submitted a forma...
Redeye has a largely neutral take on Nanologica’s Q2 2023 report in terms of the financials.
Bonzun has agreed to sell all shares in its subsidiary Bonzun Evolve to CBT-based sleep therapy comp...
Redeye provides an update on Fantasma Games ahead of its Q2-results (due 9 Aug), where we expect a s...
Q2 NOI +14% y-o-y ,-2% vs ABGSCe Higher net financials than expected, IFPM -15% vs ABGSCe Positive n...
Biometriska accesskort ger stor potential till relativt sett låg risk… Med höga säkerhetskrav, en ko...
Lipigon har aviserat ett avtal med Leaderna Therapeutics kring Lipisense.
Redeye comments on Embracer Group’s directed issue of cSEK2bn.
Redeye provides a preview ahead of SSH Communications Security Q2 '23 report, due on the 20th of Jul...
We lower adjusted EBIT by 2-3% for 2023E-25E ahead of Elanders' Q2 report – a quarter in which we ex...
Redeye is encouraged by Fluoguide carrying out a smaller directed share issue of cSEK15m in gross pr...
9% organic growth expected in Q2 Slight increase in estimates from M&A Seamless CEO transition Q2e:...
We expect a return to sales growth in H2 '23 Resilient despite the tight market conditions Focus on ...
Redeye provides its commentary on Wyld Networks following its recent distribution and system integra...
We are making slight modifications to our forecasts for Advenica's net sales for the second quarter,...
Q2 report due on Thursday 20 July Price hikes fading, but volumes are still declining 11x '23e EV/EB...
Q2 report due on Wednesday, 12 July Demand likely slowing, mainly in Electronics 10x EV/EBITA (adj.
